GYRE Fundamental Analysis - GYRE THERAPEUTICS INC

Fundamental Rating

Overall GYRE gets a fundamental rating of 5 out of 10. We evaluated GYRE against 557 industry peers in the Biotechnology industry. GYRE has an excellent financial health rating, but there are some minor concerns on its profitability. GYRE is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GYRE was profitable.

In the past year GYRE has reported a negative cash flow from operations.

In the past 5 years GYRE reported 4 times negative net income.

In the past 5 years GYRE reported 4 times negative operating cash flow.

1.2 Ratios

GYRE's Return On Assets of 5.59% is amongst the best of the industry. GYRE outperforms 92.64% of its industry peers.

The Return On Equity of GYRE (10.64%) is better than 94.08% of its industry peers.

The Return On Invested Capital of GYRE (7.26%) is better than 93.72% of its industry peers.

		Industry Rank	Sector Rank
ROA	5.59%
ROE	10.64%
ROIC	7.26%

ROA(3y)-33.04%

ROA(5y)-63.26%

ROE(3y)-80.93%

ROE(5y)-106.13%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 7.20%, GYRE belongs to the best of the industry, outperforming 92.10% of the companies in the same industry.

GYRE's Operating Margin of 10.36% is amongst the best of the industry. GYRE outperforms 93.90% of its industry peers.

The Gross Margin of GYRE (96.23%) is better than 95.87% of its industry peers.

		Industry Rank	Sector Rank
OM	10.36%
PM (TTM)	7.2%
GM	96.23%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GYRE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

Compared to 1 year ago, GYRE has more shares outstanding

GYRE has more shares outstanding than it did 5 years ago.

There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

GYRE has an Altman-Z score of 7.89. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 7.89, GYRE belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.

GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	7.89

ROIC/WACC0.74

WACC9.79%

2.3 Liquidity

GYRE has a Current Ratio of 3.60. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.

GYRE has a Current ratio (3.60) which is comparable to the rest of the industry.

A Quick Ratio of 3.19 indicates that GYRE has no problem at all paying its short term obligations.

GYRE has a Quick ratio of 3.19. This is in the lower half of the industry: GYRE underperforms 61.04% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.6
Quick Ratio	3.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 103.86%, which is quite impressive.

Looking at the last year, GYRE shows a very negative growth in Revenue. The Revenue has decreased by -28.43% in the last year.

GYRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.34% yearly.

EPS 1Y (TTM)103.86%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-63.9%

Revenue 1Y (TTM)-28.43%

Revenue growth 3Y143.34%

Revenue growth 5YN/A

Sales Q2Q%-18.82%

3.2 Future

Based on estimates for the next years, GYRE will show a very strong growth in Earnings Per Share. The EPS will grow by 77.26% on average per year.

Based on estimates for the next years, GYRE will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.

EPS Next Y-61.14%

EPS Next 2Y94.64%

EPS Next 3Y77.26%

EPS Next 5YN/A

Revenue Next Year4.24%

Revenue Next 2Y40.6%

Revenue Next 3Y43.57%

Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 107.00 indicates a quite expensive valuation of GYRE.

GYRE's Price/Earnings ratio is rather cheap when compared to the industry. GYRE is cheaper than 91.02% of the companies in the same industry.

The average S&P500 Price/Earnings ratio is at 27.30. GYRE is valued rather expensively when compared to this.

Based on the Price/Forward Earnings ratio of 6.28, the valuation of GYRE can be described as very cheap.

GYRE's Price/Forward Earnings ratio is rather cheap when compared to the industry. GYRE is cheaper than 98.38% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, GYRE is valued rather cheaply.

		Industry Rank	Sector Rank
PE	107
Fwd PE	6.28

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GYRE is valued cheaply inside the industry as 92.10% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	56.82

4.3 Compensation for Growth

GYRE's earnings are expected to grow with 77.26% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y94.64%

EPS Next 3Y77.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GYRE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GYRE THERAPEUTICS INC

NASDAQ:GYRE (7/11/2025, 8:19:59 PM)

After market: 7.55 +0.06 (+0.8%)

7.49

-0.32 (-4.1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-09 2025-05-09/bmo

Earnings (Next)08-11 2025-08-11

Inst Owners2.99%

Inst Owner Change0%

Ins Owners8.65%

Ins Owner Change2.09%

Market Cap702.26M

Analysts82.86

Price Target20.4 (172.36%)

Short Float %10.55%

Short Ratio5.47

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-52.39%

Min EPS beat(2)-102.82%

Max EPS beat(2)-1.96%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)-3.79%

Min Revenue beat(2)-23.85%

Max Revenue beat(2)16.28%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)50%

EPS NQ rev (3m)50%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)7.32%

Revenue NQ rev (3m)7.32%

Revenue NY rev (1m)-0.79%

Revenue NY rev (3m)-0.79%

Valuation

		Industry Rank	Sector Rank
PE	107
Fwd PE	6.28
P/S	6.98
P/FCF	N/A
P/OCF	N/A
P/B	10.31
P/tB	11.14
EV/EBITDA	56.82

EPS(TTM)0.07

EY0.93%

EPS(NY)1.19

Fwd EY15.93%

FCF(TTM)-0.11

FCFYN/A

OCF(TTM)-0.07

OCFYN/A

SpS1.07

BVpS0.73

TBVpS0.67

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	5.59%
ROE	10.64%
ROCE	9.41%
ROIC	7.26%
ROICexc	9.94%
ROICexgc	10.6%
OM	10.36%
PM (TTM)	7.2%
GM	96.23%
FCFM	N/A

ROA(3y)-33.04%

ROA(5y)-63.26%

ROE(3y)-80.93%

ROE(5y)-106.13%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.78

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	222.77%
Cap/Sales	3.69%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.6
Quick Ratio	3.19
Altman-Z	7.89

F-Score5

WACC9.79%

ROIC/WACC0.74

Cap/Depr(3y)333.79%

Cap/Depr(5y)313.61%

Cap/Sales(3y)3.51%

Cap/Sales(5y)4.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)103.86%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-63.9%

EPS Next Y-61.14%

EPS Next 2Y94.64%

EPS Next 3Y77.26%

EPS Next 5YN/A

Revenue 1Y (TTM)-28.43%

Revenue growth 3Y143.34%

Revenue growth 5YN/A

Sales Q2Q%-18.82%

Revenue Next Year4.24%

Revenue Next 2Y40.6%

Revenue Next 3Y43.57%

Revenue Next 5Y-14.87%

EBIT growth 1Y-67.25%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y61.87%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y75.54%

OCF growth 3YN/A

OCF growth 5YN/A

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens